ClinicalTrials.gg
Not yet recruitingNCT07759869Updated Aug 12, 2026

A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia

A Phase 3 interventional study of HS-10380 in SCHIZOPHRENIA 1 (Disorder), sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 250 studies in Schizophrenia with a site in China — 62 open to participants now, 66 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
21st of 215
500 · median 100
Started
2026
with 24 others
Phase 3
35 of 250
3 open now
Primary completion
2028-07
later than 53 of 65 live
Registered
239th of 250
by date
Lead sponsor
6 of 250
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 250 studies in Schizophrenia with a site in China, this one is the 21st largest by planned enrollment of the 215 interventional ones that give a count, is one of 25 that started in 2026, is one of 35 in phase 3, reaches primary completion later than 53 of the 65 other live ones, and was the 239th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

62 of the 250 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 250 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this open-label phase 3 study is to evaluate the safety of HS-10380 on the incidence, severity, relationship to investigational product of adverse events (AE), serious adverse events (SAE), and adverse events leading to study drug discontinuationin Chinese adult participants with schizophrenia.

Read the detailed description

The study will comprise 3 periods : a Screening Period, an Open-Label Treatment Period during which participants will be treated for 52 weeks and a 14-day Follow-up Period before an End of Study (EOS) Visit. The total study duration for each participant on this study is 57 weeks.

03

Conditions studied

  • SCHIZOPHRENIA 1 (Disorder)

Browse trials for

Keywords

  • Schizophrenia, Long-term, open-label, HS-10380
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is aged 18-65 years, inclusive, at screening.
  • must be ≥18.0 and ≤40.0 kg/m² at screening.
  • Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the criteria.
  • Willing and able to give /assent as per local requirements.
  • Participants are willing and able to discontinue all antipsychotic medications prior to the baseline visit, as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Participant has a current diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia.
  • Judged by the investigator as having treatment-resistant schizophrenia.
  • Patients with risk of violent or destructive behavior, or suicidal risk.
  • History or presence of disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  • Any surgical condition or medical condition that may significantly affect drug absorption, distribution, metabolism, and excretion, or that may pose a risk to trial participants, such as history of gastrointestinal surgery (gastrectomy, gastroenterostomy, bowel resection, etc.), urinary tract obstruction, or dysuria.
  • History of severe allergic reactions.
  • Female patients who are pregnant, in puerperium, or lactating at screening or baseline.
  • History of drug abuse within 1 year prior to screening.
  • History of alcohol abuse within 6 months prior to screening.
  • Abnormal physical examination findings、vital signs or 12-lead (ECG) at screening .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    HS-10380 (1.5-6mg)

    Drug: HS-10380

Interventions

  • Oral;QD;W1:dose titration; W1-2:dose adjust to optimal level;Week 3-52:stable dose.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE)

    TEAEs are defined as events with an onset date on or after the first dose of HS-10380. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event.

    Time frame: From first dose to end of study (Up to approximately 54 weeks )

  2. Incidence and severity of serious adverse events (SAE)

    An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization ; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect.

    Time frame: From first dose to end of study (Up to approximately 52 weeks)

  3. Incidence of Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation

    TEAEs are defined as events with an onset date on or after the first dose of HS-10380. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event.

    Time frame: From first dose to end of study (Up to approximately 54 weeks )

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions . PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.

    Time frame: Open-label extension baseline, week 52

  2. Change from Baseline in Clinical Global Impression-Severity (CGI-S) Score

    The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.

    Time frame: Open-label extension baseline, week 52

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2028, 22 months later.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 22 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2026
First posted
Aug 12, 2026
StartEst.
Sep 9, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07759869
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Sep 9, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Tianmei Si
Contact
si.tian-mei@163.com
010-62723761

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10380

Start the discussion